TNF and cancer: Friends and/or foes?

The Inflammatory Milieu of Tumors: Cytokines and Chemokines that Affect Tumor Growth and Metastasis

Volumn , Issue , 2012, Pages 29-56

  Bertazza, Loris ^a,b   Mocellin, Simone ^a   DeWitte, Mark ^c   Nitti, Donato ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c Haematology Oncology Clinical RandD CSL Ltd   (Australia)

Author keywords

Antineoplastic agent; Antitumor therapy; Tumor necrosis factor (TNF)

Indexed keywords

EID: 84882693001     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2174/978160805256111201010029     Document Type: Chapter

References (255)

1. Mocellin S, Mandruzzato S, Bronte V, Lise M, Nitti D. Part I: Vaccines for solid tumours. Lancet Oncol. 2004 Nov;5(11):681-9.
2. Rosenberg SA. Principles and practice of the biologic therapy of cancer: Lippincott Williams & Wilkins; 2000.
3. Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):185-91.
4. Coley W. Further observations upon the treatment of malignant tumors with the toxins of erysipelas and Bacillus prodigiosus with a report of 160 cases. Bull Johns Hopkins Hospital. 1896;7:157.
5. Nauts HC. The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D. Reviewed in the light of modern research. Cancer Res. 1946;6:205-16.
6. Nauts HC. A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley's mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med Scand Suppl. 1953;276:1-103.
7. Shear MJ. Chemical treatment of tumors. IX. Reactions of mice with primary subcutaneous tumors to injection of a hemorrhageproducing bacterial polysaccharide. J Natl Cancer Inst 1944;44: 461-76.
8. O'Malley WE. Action of bacterial polysaccharide on tumours. II. Damage of sarcoma 37 by serum of mice treated with serratia marcescens polysaccharide, and induced tolerance. J Natl Cancer Inst. 1962;29:1169-75.
9. Carswell EAea. An endotoxin-induced serum factor that causes necrosis of tumours. Proc Natl Acad Sci USA. 1975;72:3666-70.
10. Granger GA. Lymphocyte in vitro cytotoxicity: mechanisms of immune and non-immune small lymphocyte mediated target L cell destruction. J Immunol. 1968;101:111-20.
11. Aggarwal BBea. Human tumor necrosis factor. Production, purification, and characterisation. J Biol Chem. 1985;260:2345-54.
12. Aggarwal BB. Human lymphotoxin. Production by a lymphoblastoid cell line, purification, and initial characterization. J Biol Chem. 1984;259:686-91.
13. Aggarwal BB. Primary structure of human lymphotoxin derived from 1788 lymphoblastoid cell line. J Biol Chem. 1985;260:2334-44.
14. Aggarwal BB. Characterization of receptors for human tumour necrosis factor and their regulation by γ-interferon. Nature. 1985;318:665-7.
15. Beutler B, Greenwald D, Hulmes JD, Chang M, Pan YC, Mathison J, et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature. 1985 Aug 8-14;316(6028):552-4.
16. Takeda K, Iwamoto S, Sugimoto H, Takuma T, Kawatani N, Noda M, et al. Identity of differentiation inducing factor and tumour necrosis factor. Nature. 1986 Sep 25-Oct 1;323(6086):338-40.
17. Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol. 1999;26:16-21.
18. Feldmann M. Many cytokines are very useful therapeutic targets in disease. J Clin Invest. 2008;118:3533-6.
19. Elliott MJea. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994;344:1105-10.
20. Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol. 1998 Oct;10(5):573-80.
21. Eggermont AM, ten Hagen TL. Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy. Curr Oncol Rep. 2003 Mar;5(2):79-80.
22. Aggarwal BB, Shishodia S, Ashikawa K, Bharti AC. The role of TNF and its family members in inflammation and cancer: lessons from gene deletion. Curr Drug Targets Inflamm Allergy. 2002 Dec;1(4):327-41.
23. Aggarwal B. Signaling pathways of the TNF superfamily: a double edged sword. Nat Rev Immunol. 2003;3:745-56.
24. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001 Feb 23;104(4):487-501.
25. Croft M. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat Rev Immunol. 2003 Aug;3(8):609-20.
26. Grivennikov SI, Tumanov AV, Liepinsh DJ, Kruglov AA, Marakusha BI, Shakhov AN, et al. Distinct and nonredundant in vivo functions of TNF produced by t cells and macrophages/neutrophils: protective and deleterious effects. Immunity. 2005 Jan;22(1):93-104.
27. Aggarwal BB. Nuclear factor-kappaB: the enemy within. Cancer Cell. 2004 Sep;6(3):203-8.
28. Cytokine Reference [database on the Internet]. Academic Press. 2000.
29. Tello K, Christiansen H, Gurleyen H, Dudas J, Rave-Frank M, Hess CF, et al. Irradiation leads to apoptosis of Kupffer cells by a Hsp27-dependant pathway followed by release of TNF-alpha. Radiat Environ Biophys. 2008 Jul;47(3):389-97.
30. Bemelmans MH, van Tits LJ, Buurman WA. Tumor necrosis factor: function, release and clearance. Crit Rev Immunol. 1996;16(1):1-11.
31. Tansey MG, Szymkowski DE. The TNF superfamily in 2009: new pathways, new indications, and new drugs. Drug Discov Today. 2009 Dec;14(23-24):1082-8.
32. Vinay DS, Kwon BS. TNF superfamily: costimulation and clinical applications. Cell Biol Int. 2009 Apr;33(4):453-65.
33. Mocellin S, Nitti D. TNF and cancer: the two sides of the coin. Front Biosci. 2008;13:2774-83.
34. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science. 2002 May 31;296(5573):1634-5.
35. Ghosh S, Karin M. Missing pieces in the NF-kappaB puzzle. Cell. 2002 Apr;109 Suppl:S81-96.
36. Li X, Yang Y, Ashwell JD. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature. 2002 Mar 21;416(6878):345-7.
37. Wu Y, Zhou BP. TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. Br J Cancer. 2010 Feb 16;102(4):639-44.
38. Lombardi A, Cantini G, Mello T, Francalanci M, Gelmini S, Cosmi L, et al. Molecular mechanisms underlying the pro-inflammatory synergistic effect of tumor necrosis factor alpha and interferon gamma in human microvascular endothelium. Eur J Cell Biol. 2009 Dec;88(12):731-42.
39. Leist M, Jaattela M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol. 2001 Aug;2(8):589-98.
40. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000 Jul 7;102(1):33-42.
41. Foghsgaard L, Wissing D, Mauch D, Lademann U, Bastholm L, Boes M, et al. Cathepsin B acts as a dominant execution protease in tumor cell apoptosis induced by tumor necrosis factor. J Cell Biol. 2001 May 28;153(5):999-1010.
42. Kim JW, Choi EJ, Joe CO. Activation of death-inducing signaling complex (DISC) by pro-apoptotic C-terminal fragment of RIP. Oncogene. 2000 Sep 14;19(39):4491-9.
43. Varfolomeev EE, Ashkenazi A. Tumor necrosis factor: an apoptosis JuNKie? Cell. 2004 Feb 20;116(4):491-7.
44. Orlowski RZ, Baldwin AS, Jr. NF-kappaB as a therapeutic target in cancer. Trends Mol Med. 2002 Aug;8(8):385-9.
45. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997 Jul 10;388(6638):190-5.
46. Jaattela M, Benedict M, Tewari M, Shayman JA, Dixit VM. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene. 1995 Jun 15;10(12):2297-305.
47. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptoror drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene. 2001 Sep 13;20(41):5865-77.
48. Gulbins E, Grassme H. Ceramide and cell death receptor clustering. Biochim Biophys Acta. 2002 Dec 30;1585(2-3):139-45.
49. De Nadai C, Sestili P, Cantoni O, Lievremont JP, Sciorati C, Barsacchi R, et al. Nitric oxide inhibits tumor necrosis factor-alpha-induced apoptosis by reducing the generation of ceramide. Proc Natl Acad Sci U S A. 2000;97(10):5480-5.
50. Liu B, Andrieu-Abadie N, Levade T, Zhang P, Obeid LM, Hannun YA. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J Biol Chem. 1998 May 1;273(18):11313-20.
51. Fehrenbacher N, Gyrd-Hansen M, Poulsen B, Felbor U, Kallunki T, Boes M, et al. Sensitization to the lysosomal cell death pathway upon immortalization and transformation. Cancer Res. 2004 Aug 1;64(15):5301-10.
52. Polunovsky VA, Wendt CH, Ingbar DH, Peterson MS, Bitterman PB. Induction of endothelial cell apoptosis by TNF alpha: modulation by inhibitors of protein synthesis. Exp Cell Res. 1994 Oct;214(2):584-94.
53. Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol. 2003 Jul;4(7):429-37.
54. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975;72(9):3666-70.
55. Palladino MA, Jr., Shalaby MR, Kramer SM, Ferraiolo BL, Baughman RA, Deleo AB, et al. Characterization of the antitumor activities of human tumor necrosis factor-alpha and the comparison with other cytokines: induction of tumor-specific immunity. J Immunol. 1987 Jun 1;138(11):4023-32.
56. Shimomura K, Manda T, Mukumoto S, Kobayashi K, Nakano K, Mori J. Recombinant human tumor necrosis factoralpha: thrombus formation is a cause of anti-tumor activity. Int J Cancer. 1988 Feb 15;41(2):243-7.
57. Van de Wiel PA, Bloksma N, Kuper CF, Hofhuis FM, Willers JM. Macroscopic and microscopic early effects of tumour necrosis factor on murine Meth A sarcoma, and relation to curative activity. J Pathol. 1989 Jan;157(1):65-73.
58. Furrer M, Altermatt HJ, Ris HB, Althaus U, Ruegg C, Lienard D, et al. Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system. Melanoma Res. 1997 Aug;7 Suppl 2:S43-9.
59. Balkwill FR, Lee A, Aldam G, Moodie E, Thomas JA, Tavernier J, et al. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res. 1986 Aug;46(8):3990-3.
60. Fajardo LF, Kwan HH, Kowalski J, Prionas SD, Allison AC. Dual role of tumor necrosis factor-alpha in angiogenesis. Am J Pathol. 1992 Mar;140(3):539-44.
61. Watanabe N, Niitsu Y, Umeno H, Kuriyama H, Neda H, Yamauchi N, et al. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res. 1988 Apr 15;48(8):2179-83.
62. Naredi PL, Lindner PG, Holmberg SB, Stenram U, Peterson A, Hafstrom LR. The effects of tumour necrosis factor alpha on the vascular bed and blood flow in an experimental rat hepatoma. Int J Cancer. 1993;54(4):645-9.
63. Mule JJ, Asher A, McIntosh J, Lafreniere R, Shiloni E, Lefor A, et al. Antitumor effect of recombinant tumor necrosis factor-alpha against murine sarcomas at visceral sites: tumor size influences the response to therapy. Cancer Immunol Immunother. 1988;26(3):202-8.
64. van Etten B, de Vries MR, van IMG, Lans TE, Guetens G, Ambagtsheer G, et al. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion. Br J Cancer. 2003 Jan 27;88(2):314-9.
65. Olieman AF, van Ginkel RJ, Hoekstra HJ, Mooyaart EL, Molenaar WM, Koops HS. Angiographic response of locally advanced soft-tissue sarcoma following hyperthermic isolated limb perfusion with tumor necrosis factor. Ann Surg Oncol. 1997;4(1):64-9.
66. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 1997 Jan 24;275(5299):547-50.
67. Zhang Y, Deng Y, Wendt T, Liliensiek B, Bierhaus A, Greten J, et al. Intravenous somatic gene transfer with antisense tissue factor restores blood flow by reducing tumor necrosis factor-induced tissue factor expression and fibrin deposition in mouse meth-A sarcoma. J Clin Invest. 1996 May 15;97(10):2213-24.
68. Bierhaus A, Zhang Y, Deng Y, Mackman N, Quehenberger P, Haase M, et al. Mechanism of the tumor necrosis factor alpha-mediated induction of endothelial tissue factor. J Biol Chem. 1995 Nov 3;270(44):26419-32.
69. Napoleone E, Di Santo A, Lorenzet R. Monocytes upregulate endothelial cell expression of tissue factor: a role for cell-cell contact and cross-talk. Blood. 1997 Jan 15;89(2):541-9.
70. Lewis JC, Jones NL, Hermanns MI, Rohrig O, Klein CL, Kirkpatrick CJ. Tissue factor expression during coculture of endothelial cells and monocytes. Exp Mol Pathol. 1995 Jun;62(3):207-18.
71. Vandenabeele P, Declercq W, Vercammen D, Van de Craen M, Grooten J, Loetscher H, et al. Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma. J Exp Med. 1992 Oct 1;176(4):1015-24.
72. Gregory SA, Morrissey JH, Edgington TS. Regulation of tissue factor gene expression in the monocyte procoagulant response to endotoxin. Mol Cell Biol. 1989 Jun;9(6):2752-5.
73. Stoelcker B, Ruhland B, Hehlgans T, Bluethmann H, Luther T, Mannel DN. Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am J Pathol. 2000;156(4):1171-6.
74. Ruegg C, Yilmaz A, Bieler G, Bamat J, Chaubert P, Lejeune FJ. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat Med. 1998;4(4):408-14.
75. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, et al. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 1994 Dec 30;79(7):1157-64.
76. Mocellin S, Provenzano M, Rossi CR, Pilati P, Scalerta R, Lise M, et al. Induction of endothelial nitric oxide synthase expression by melanoma sensitizes endothelial cells to tumor necrosis factor-driven cytotoxicity. Clin Cancer Res. 2004 Oct 15;10(20):6879-86.
77. Manusama ER, Nooijen PT, Stavast J, Durante NM, Marquet RL, Eggermont AM. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br J Surg. 1996;83(4):551-5.
78. Nooijen PT, Manusama ER, Eggermont AM, Schalkwijk L, Stavast J, Marquet RL, et al. Synergistic effects of TNFalpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br J Cancer. 1996;74(12):1908-15.
79. Seynhaeve AL, de Wilt JH, van Tiel ST, Eggermont AM, ten Hagen TL. Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity. Br J Cancer. 2002;86(7):1174-9.
80. van der Veen AH, de Wilt JH, Eggermont AM, van Tiel ST, Seynhaeve AL, ten Hagen TL. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF- alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects. Br J Cancer. 2000;82(4):973-80.
81. Bauer TW, Gutierrez M, Dudrick DJ, Li J, Blair IA, Menon C, et al. A human melanoma xenograft in a nude rat responds to isolated limb perfusion with TNF plus melphalan. Surgery. 2003 Apr;133(4):420-8.
82. Alexander HR, Jr., Libutti SK, Bartlett DL, Pingpank JF, Kranda K, Helsabeck C, et al. Hepatic vascular isolation and perfusion for patients with progressive unresectable liver metastases from colorectal carcinoma refractory to previous systemic and regional chemotherapy. Cancer. 2002 Aug 15;95(4):730-6.
83. Posner M, Lienard D, Lejeune FJ, Rosenfelder D, Kirkwood JM, editors. Hyperthermic isolated limb perfusion (HILP) with tumor necrosis factor alpha (TNF) alone for metastatic in-transit melanoma 1994.
84. Seong J, Milross CG, Hunter NR, Shin HC, Milas L. Potentiation of antitumor efficacy of paclitaxel by recombinant tumor necrosis factor-alpha. Anticancer Drugs. 1997 Jan;8(1):80-7.
85. Buell JF, Reed E, Lee KB, Parker RJ, Venzon DJ, Amikura K, et al. Synergistic effect and possible mechanisms of tumor necrosis factor and cisplatin cytotoxicity under moderate hyperthermia against gastric cancer cells. Ann Surg Oncol. 1997;4(2):141-8.
86. Lejeune FJ. Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. J Clin Invest. 2002 Aug;110(4):433-5.
87. de Wilt JH, ten Hagen TL, de Boeck G, van Tiel ST, de Bruijn EA, Eggermont AM. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion. Br J Cancer. 2000;82(5):1000-3.
88. Duan L, Aoyagi M, Tamaki M, Yoshino Y, Morimoto T, Wakimoto H, et al. Impairment of both apoptotic and cytoprotective signalings in glioma cells resistant to the combined use of cisplatin and tumor necrosis factor alpha. Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):234-43.
89. Choi KH, Choi HY, Ko JK, Park SS, Kim YN, Kim CW. Transcriptional regulation of TNF family receptors and Bcl-2 family by chemotherapeutic agents in murine CT26 cells. J Cell Biochem. 2004 Feb 1;91(2):410-22.
90. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, et al. Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med. 2002 Mar;8(3):274-81.
91. Havell EA, Fiers W, North RJ. The antitumor function of tumor necrosis factor (TNF), I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J Exp Med. 1988 Mar 1;167(3):1067-85.
92. Vujanovic NL. Role of TNF family ligands in antitumor activity of natural killer cells. Int Rev Immunol. 2001 Jun;20(3-4):415-37.
93. Mocellin S, Provenzano M, Lise M, Nitti D, Rossi CR. Increased TIA-1 gene expression in the tumor microenvironment after locoregional administration of tumor necrosis factor-alpha to patients with soft tissue limb sarcoma. Int J Cancer. 2003 Nov 1;107(2):317-22.
94. Prevost-Blondel A, Roth E, Rosenthal FM, Pircher H. Crucial role of TNF-alpha in CD8 T cell-mediated elimination of 3LL-A9 Lewis lung carcinoma cells in vivo. J Immunol. 2000 Apr 1;164(7):3645-51.
95. Poehlein CH, Hu HM, Yamada J, Assmann I, Alvord WG, Urba WJ, et al. TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells. J Immunol. 2003 Feb 15;170(4):2004-13.
96. Baxevanis CN, Voutsas IF, Tsitsilonis OE, Tsiatas ML, Gritzapis AD, Papamichail M. Compromised anti-tumor responses in tumor necrosis factor-alpha knockout mice. Eur J Immunol. 2000 Jul;30(7):1957-66.
97. Figdor CG, De Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004 May;10(5):475-80.
98. Burgdorf SK, Claesson MH, Nielsen HJ, Rosenberg J. Changes in cytokine and biomarker blood levels in patients with colorectal cancer during dendritic cell-based vaccination. Acta Oncol. 2009 Jul 27:1-8.
99. Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev. 2002 Apr;13(2):135-41.
100. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004 Jul;4(7):540-50.
101. Kirstein M, Baglioni C. Tumor necrosis factor stimulates proliferation of human osteosarcoma cells and accumulation of c-myc messenger RNA. J Cell Physiol. 1988 Mar;134(3):479-84.
102. Wu S, Boyer CM, Whitaker RS, Berchuck A, Wiener JR, Weinberg JB, et al. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res. 1993 Apr 15;53(8):1939-44.
103. Ferrajoli A, Keating MJ, Manshouri T, Giles FJ, Dey A, Estrov Z, et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood. 2002 Aug 15;100(4):1215-9.
104. Liu RY, Fan C, Liu G, Olashaw NE, Zuckerman KS. Activation of p38 mitogen-activated protein kinase is required for tumor necrosis factor-alpha -supported proliferation of leukemia and lymphoma cell lines. J Biol Chem. 2000 Jul 14;275(28):21086-93.
105. Tselepis C, Perry I, Dawson C, Hardy R, Darnton SJ, McConkey C, et al. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene. 2002 Sep 5;21(39):6071-81.
106. Hagemann T, Wilson J, Kulbe H, Li NF, Leinster DA, Charles K, et al. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol. 2005 Jul 15;175(2):1197-205.
107. Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson JL. The inflammatory cytokine tumor necrosis factoralpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res. 2005 Nov 15;65(22):10355-62.
108. Stathopoulos GT, Sherrill TP, Han W, Sadikot RT, Yull FE, Blackwell TS, et al. Host nuclear factor-kappaB activation potentiates lung cancer metastasis. Mol Cancer Res. 2008 Mar;6(3):364-71.
109. Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, Nakshatri H. NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene. 2007 Feb 1;26(5):711-24.
110. Chuang MJ, Sun KH, Tang SJ, Deng MW, Wu YH, Sung JS, et al. Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Sci. 2008 May;99(5):905-13.
111. Julien S, Puig I, Caretti E, Bonaventure J, Nelles L, van Roy F, et al. Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene. 2007 Nov 22;26(53):7445-56.
112. Rivas MA, Carnevale RP, Proietti CJ, Rosemblit C, Beguelin W, Salatino M, et al. TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways. Exp Cell Res. 2008 Feb 1;314(3):509-29.
113. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med. 1999 Jul;5(7):828-31.
114. Komori A, Yatsunami J, Suganuma M, Okabe S, Abe S, Sakai A, et al. Tumor necrosis factor acts as a tumor promoter in BALB/3T3 cell transformation. Cancer Res. 1993 May 1;53(9):1982-5.
115. Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, Fujiki H. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res. 1999 Sep 15;59(18):4516-8.
116. Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000 Jan 1;60(1):184-90.
117. Dhar A, Young MR, Colburn NH. The role of AP-1, NF-kappaB and ROS/NOS in skin carcinogenesis: the JB6 model is predictive. Mol Cell Biochem. 2002 May-Jun;234-235(1-2):185-93.
118. Arnott CH, Scott KA, Moore RJ, Hewer A, Phillips DH, Parker P, et al. Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1-dependent pathway. Oncogene. 2002 Jul 18;21(31):4728-38.
119. Korner H, Cretney E, Wilhelm P, Kelly JM, Rollinghoff M, Sedgwick JD, et al. Tumor necrosis factor sustains the generalized lymphoproliferative disorder (gld) phenotype. J Exp Med. 2000 Jan 3;191(1):89-96.
120. Arnott CH, Scott KA, Moore RJ, Robinson SC, Thompson RG, Balkwill FR. Expression of both TNF-alpha receptor subtypes is essential for optimal skin tumour development. Oncogene. 2004 Mar 11;23(10):1902-10.
121. Knight B, Yeoh GC, Husk KL, Ly T, Abraham LJ, Yu C, et al. Impaired preneoplastic changes and liver tumor formation in tumor necrosis factor receptor type 1 knockout mice. J Exp Med. 2000 Dec 18;192(12):1809-18.
122. Orosz P, Echtenacher B, Falk W, Ruschoff J, Weber D, Mannel DN. Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med. 1993 May 1;177(5):1391-8.
123. Waterston AM, Salway F, Andreakos E, Butler DM, Feldmann M, Coombes RC. TNF autovaccination induces self anti-TNF antibodies and inhibits metastasis in a murine melanoma model. Br J Cancer. 2004 Mar 22;90(6):1279-84.
124. Kitakata H, Nemoto-Sasaki Y, Takahashi Y, Kondo T, Mai M, Mukaida N. Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Res. 2002 Nov 15;62(22):6682-7.
125. Malik ST, Naylor MS, East N, Oliff A, Balkwill FR. Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer. 1990;26(10):1031-4.
126. Qin Z, Kruger-Krasagakes S, Kunzendorf U, Hock H, Diamantstein T, Blankenstein T. Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis. J Exp Med. 1993 Jul 1;178(1):355-60.
127. Leber TM, Balkwill FR. Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF). Br J Cancer. 1998 Sep;78(6):724-32.
128. Katerinaki E, Evans GS, Lorigan PC, MacNeil S. TNF-alpha increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes. Br J Cancer. 2003 Sep 15;89(6):1123-9.
129. Nabors LB, Suswam E, Huang Y, Yang X, Johnson MJ, King PH. Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: a role for RNA stabilization and HuR. Cancer Res. 2003 Jul 15;63(14):4181-7.
130. Joseph IB, Isaacs JT. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents. J Natl Cancer Inst. 1998 Nov 4;90(21):1648-53.
131. Nesbit M, Schaider H, Miller TH, Herlyn M. Low-level monocyte chemoattractant protein-1 stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J Immunol. 2001 Jun 1;166(11):6483-90.
132. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, et al. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol. 1997 Jul;17(7):4015-23.
133. Cheng N, Chen J. Tumor necrosis factor-alpha induction of endothelial ephrin A1 expression is mediated by a p38 MAPK- and SAPK/JNK-dependent but nuclear factor-kappa B-independent mechanism. J Biol Chem. 2001 Apr 27;276(17):13771-7.
134. De Cesaris P, Starace D, Starace G, Filippini A, Stefanini M, Ziparo E. Activation of Jun N-terminal kinase/stressactivated protein kinase pathway by tumor necrosis factor alpha leads to intercellular adhesion molecule-1 expression. J Biol Chem. 1999 Oct 8;274(41):28978-82.
135. Kawai N, Tsuji S, Tsujii M, Ito T, Yasumaru M, Kakiuchi Y, et al. Tumor necrosis factor alpha stimulates invasion of Src-activated intestinal cells. Gastroenterology. 2002 Feb;122(2):331-9.
136. Mantovani G, Maccio A, Lai P, Massa E, Ghiani M, Santona MC. Cytokine activity in cancer-related anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate. Semin Oncol. 1998 Apr;25(2 Suppl 6):45-52.
137. Dalum I, Butler DM, Jensen MR, Hindersson P, Steinaa L, Waterston AM, et al. Therapeutic antibodies elicited by immunization against TNF-alpha. Nat Biotechnol. 1999 Jul;17(7):666-9.
138. Haslett PA. Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol. 1998 Apr;25(2 Suppl 6):53-7.
139. Tisdale MJ. Cancer cachexia. Langenbecks Arch Surg. 2004 Aug;389(4):299-305.
140. Wiedenmann B, Malfertheiner P, Friess H, Ritch P, Arseneau J, Mantovani G, et al. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol. 2008 Jan;6(1):18-25.
141. Michalaki V, Syrigos K, Charles P, Waxman J. Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer. 2004 Jun 14;90(12):2312-6.
142. Dosquet C, Coudert MC, Lepage E, Cabane J, Richard F. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma? Clin Cancer Res. 1997 Dec;3(12 Pt 1):2451-8.
143. Warzocha K, Bienvenu J, Ribeiro P, Moullet I, Dumontet C, Neidhardt-Berard EM, et al. Plasma levels of tumour necrosis factor and its soluble receptors correlate with clinical features and outcome of Hodgkin's disease patients. Br J Cancer. 1998 Jun;77(12):2357-62.
144. Tsimberidou AM, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M, et al. The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes. Cancer. 2008 Oct 1;113(7):1605-13.
145. Dredge K, Marriott JB, Dalgleish AG. Immunological effects of thalidomide and its chemical and functional analogs. Crit Rev Immunol. 2002;22(5-6):425-37.
146. D'Amato RJ, Lentzsch S, Anderson KC, Rogers MS. Mechanism of action of thalidomide and 3-aminothalidomide in multiple myeloma. Semin Oncol. 2001 Dec;28(6):597-601.
147. Rossi CR, Foletto M, Pilati P, Mocellin S, Lise M. Isolated limb perfusion in locally advanced cutaneous melanoma. Semin Oncol. 2002;29(4):400-9.
148. Rossi CR, Mocellin S, Pilati P, Foletto M, Nitti D, Lise M. TNFalpha-based isolated perfusion for limb-threatening soft tissue sarcomas: state of the art and future trends. J Immunother. 2003 Jul-Aug;26(4):291-300.
149. Christoforidis D, Martinet O, Lejeune FJ, Mosimann F. Isolated liver perfusion for non-resectable liver tumours: a review. Eur J Surg Oncol. 2002;28(8):875-90.
150. Cornett WR, McCall LM, Petersen RP, Ross MI, Briele HA, Noyes RD, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. J Clin Oncol. 2006 Sep 1;24(25):4196-201.
151. Di Filippo F, Giacomini P, Rossi CR, Santinami M, Garinei R, Anza M, et al. Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO). In Vivo. 2009 Mar-Apr;23(2):363-7.
152. Vilcek J, Feldmann M. Historical review: Cytokines as therapeutics and targets of therapeutics. Trends Pharmacol Sci. 2004 Apr;25(4):201-9.
153. Mossner R, Schon MP, Reich K. Tumor necrosis factor antagonists in the therapy of psoriasis. Clin Dermatol. 2008 Sep-Oct;26(5):486-502.
154. Kajiwara K, Saito A, Ogata S, Tanihara M. Synthetic peptides corresponding to ligand-binding region of death receptors, DR5, Fas, and TNFR, specifically inhibit cell death mediated by the death ligands, respectively. Biochim Biophys Acta. 2004 Jun 1;1699(1-2):131-7.
155. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007 Nov;13(11):1323-32.
156. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002 Dec;46(12):3151-8.
157. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004 Jun;50(6):1740-51.
158. Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum. 2009 Nov;60(11):3180-9.
159. Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol. 2003 Sep;4(9):565-73.
160. Tsimberidou AM, Waddelow T, Kantarjian HM, Albitar M, Giles FJ. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment. Leuk Res. 2003 May;27(5):375-80.
161. Du Bois JS, Trehu EG, Mier JW, Shapiro L, Epstein M, Klempner M, et al. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol. 1997 Mar;15(3):1052-62.
162. Gerspach J, Pfizenmaier K, Wajant H. Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects. Biofactors. 2009 Jul-Aug;35(4):364-72.
163. Van Ostade X, Vandenabeele P, Everaerdt B, Loetscher H, Gentz R, Brockhaus M. Human TNF mutants with selective activity on the p55 receptor. Nature 1993;361:266-9.
164. Berkova N, Lemay A, Korobko V, Shingarova L, Sagaidak L, Goupil S. Tumor necrosis factor mutants with selective cytotoxic activity. Cancer Detect Prev. 1999;23(1):1-7.
165. Ameloot P, Brouckaert P. Production and characterization of receptor-specific TNF muteins. Methods Mol Med. 2004;98:33-46.
166. Sato T, Yamauchi N, Sasaki H, Takahashi M, Okamoto T, Sakamaki S, et al. An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumor necrosis factor (TNF) receptor gene transfection and mutein TNF administration. Cancer Res. 1998 Apr 15;58(8):1677-83.
167. Terlikowski SJ. Local immunotherapy with rhTNF-alpha mutein induces strong antitumor activity without overt toxicity--a review. Toxicology. 2002 Jun 5;174(3):143-52.
168. Novakovic S, Menart V, Gaberc-Porekar V, Stalc A, Sersa G, Cemazar M, et al. New TNF-alpha analogues: a powerful but less toxic biological tool against tumours. Cytokine. 1997 Aug;9(8):597-604.
169. Weichselbaum RR, Kufe DW, Hellman S, Rasmussen HS, King CR, Fischer PH, et al. Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol. 2002 Nov;3(11):665-71.
170. Senzer N, Mani S, Rosemurgy A, Nemunaitis J, Cunningham C, Guha C, et al. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol. 2004 Feb 15;22(4):592-601.
171. Bazzoni F, Regalia E. Triggering of antitumor activity through melanoma-specific transduction of a constitutively active tumor necrosis factor (TNF) R1 chimeric receptor in the absence of TNF-alpha. Cancer Res. 2001 Feb 1;61(3):1050-7.
172. Weichselbaum RR, Kufe D. Translation of the radio- and chemo-inducible TNFerade vector to the treatment of human cancers. Cancer Gene Ther. 2009 Aug;16(8):609-19.
173. Santimaria M, Moscatelli G, Viale GL, Giovannoni L, Neri G, Viti F, et al. Immunoscintigraphic detection of the EDB domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res. 2003 Feb;9(2):571-9.
174. Halin C, Gafner V, Villani ME, Borsi L, Berndt A, Kosmehl H, et al. Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res. 2003 Jun 15;63(12):3202-10.
175. Wielockx B, Lannoy K, Shapiro SD, Itoh T, Itohara S, Vandekerckhove J, et al. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nat Med. 2001 Nov;7(11):1202-8.
176. Hohenberger P, Latz E, Kettelhack C, Rezaei AH, Schumann R, Schlag PM. Pentoxifyllin attenuates the systemic inflammatory response induced during isolated limb perfusion with recombinant human tumor necrosis factor-alpha and melphalan. Ann Surg Oncol. 2003 Jun;10(5):562-8.
177. Mauceri HJ, Beckett MA, Liang H, Sutton HG, Pitroda S, Galka E, et al. Translational strategies exploiting TNFalpha that sensitize tumors to radiation therapy. Cancer Gene Ther. 2009 Apr;16(4):373-81.
178. Xiao CW, Yan X, Li Y, Reddy SA, Tsang BK. Resistance of human ovarian cancer cells to tumor necrosis factor alpha is a consequence of nuclear factor kappaB-mediated induction of Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory protein. Endocrinology. 2003 Feb;144(2):623-30.
179. Vasudevan KM, Gurumurthy S, Rangnekar VM. Suppression of PTEN expression by NF-kappa B prevents apoptosis. Mol Cell Biol. 2004 Feb;24(3):1007-21.
180. Stadheim TA, Suh N, Ganju N, Sporn MB, Eastman A. The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien- 28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells. J Biol Chem. 2002 May 10;277(19):16448-55.
181. Zwacka RM, Stark L, Dunlop MG. NF-kappaB kinetics predetermine TNF-alpha sensitivity of colorectal cancer cells. J Gene Med. 2000 Sep-Oct;2(5):334-43.
182. Wang CY, Cusack JC, Jr., Liu R, Baldwin AS, Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med. 1999 Apr;5(4):412-7.
183. Lee KY, Chang W, Qiu D, Kao PN, Rosen GD. PG490 (triptolide) cooperates with tumor necrosis factor-alpha to induce apoptosis in tumor cells. J Biol Chem. 1999 May 7;274(19):13451-5.
184. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, et al. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol. 2004 Jan 1;22(1):115-9.
185. Papandreou CN, Logothetis CJ. Bortezomib as a potential treatment for prostate cancer. Cancer Res. 2004 Aug 1;64(15):5036-43.
186. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26;348(26):2609-17.
187. An J, Sun YP, Adams J, Fisher M, Belldegrun A, Rettig MB. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res. 2003 Oct 1;9(12):4537-45.
188. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, et al. Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol. 2005 Apr 10;23(11):2469-76.
189. Weldon CB, Parker AP, Patten D, Elliott S, Tang Y, Frigo DE, et al. Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signaling. Int J Oncol. 2004 Jun;24(6):1473-80.
190. Binder C, Schulz M, Hiddemann W, Oellerich M. Induction of inducible nitric oxide synthase is an essential part of tumor necrosis factor-alpha-induced apoptosis in MCF-7 and other epithelial tumor cells. Lab Invest. 1999 Dec;79(12):1703-12.
191. Kaku Y, Nanri H, Sakimura T, Ejima K, Kuroiwa A, Ikeda M. Differential induction of constitutive and inducible nitric oxide synthases by distinct inflammatory stimuli in bovine aortic endothelial cells. Biochim Biophys Acta. 1997 Mar 27;1356(1):43-52.
192. Ganster RW, Taylor BS, Shao L, Geller DA. Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-kappa B. Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8638-43.
193. Song W, Lu X, Feng Q. Tumor necrosis factor-alpha induces apoptosis via inducible nitric oxide synthase in neonatal mouse cardiomyocytes. Cardiovasc Res. 2000 Feb;45(3):595-602.
194. Kim YM, Talanian RV, Billiar TR. Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms. J Biol Chem. 1997 Dec 5;272(49):31138-48.
195. Dimmeler S, Haendeler J, Nehls M, Zeiher AM. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta-converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like proteases. J Exp Med. 1997 Feb 17;185(4):601-7.
196. De Nadai C, Sestili P, Cantoni O, Lievremont JP, Sciorati C, Barsacchi R, et al. Nitric oxide inhibits tumor necrosis factor-alpha-induced apoptosis by reducing the generation of ceramide. Proc Natl Acad Sci U S A. 2000 May 9;97(10):5480-5.
197. Kim YM, Kim TH, Seol DW, Talanian RV, Billiar TR. Nitric oxide suppression of apoptosis occurs in association with an inhibition of Bcl-2 cleavage and cytochrome c release. J Biol Chem. 1998 Nov 20;273(47):31437-41.
198. Li J, Bombeck CA, Yang S, Kim YM, Billiar TR. Nitric oxide suppresses apoptosis via interrupting caspase activation and mitochondrial dysfunction in cultured hepatocytes. J Biol Chem. 1999 Jun 11;274(24):17325-33.
199. Torok NJ, Higuchi H, Bronk S, Gores GJ. Nitric oxide inhibits apoptosis downstream of cytochrome C release by nitrosylating caspase 9. Cancer Res. 2002 Mar 15;62(6):1648-53.
200. Thomas WJ, Thomas DL, Knezetic JA, Adrian TE. The role of oxygen-derived free radicals and nitric oxide in cytokine-induced antiproliferation of pancreatic cancer cells. Pancreas. 2002 Mar;24(2):161-8.
201. Bulotta S, Barsacchi R, Rotiroti D, Borgese N, Clementi E. Activation of the endothelial nitric-oxide synthase by tumor necrosis factor-alpha. A novel feedback mechanism regulating cell death. J Biol Chem. 2001 Mar 2;276(9):6529-36.
202. de Wilt JH, Manusama ER, van Etten B, van Tiel ST, Jorna AS, Seynhaeve AL, et al. Nitric oxide synthase inhibition results in synergistic anti-tumour activity with melphalan and tumour necrosis factor alpha-based isolated limb perfusions. Br J Cancer. 2000 Nov;83(9):1176-82.
203. Hannun YA, Luberto C. Ceramide in the eukaryotic stress response. Trends Cell Biol. 2000 Feb;10(2):73-80.
204. Garban HJ, Bonavida B. Nitric oxide disrupts H2O2-dependent activation of nuclear factor kappa B. Role in sensitization of human tumor cells to tumor necrosis factor-alpha -induced cytotoxicity. J Biol Chem. 2001 Mar 23;276(12):8918-23.
205. Erdman SE, Rao VP, Poutahidis T, Rogers AB, Taylor CL, Jackson EA, et al. Nitric oxide and TNF-alpha trigger colonic inflammation and carcinogenesis in Helicobacter hepaticus-infected, Rag2-deficient mice. Proc Natl Acad Sci U S A. 2009 Jan 27;106(4):1027-32.
206. Obrador E, Carretero J, Pellicer JA, Estrela JM. Possible mechanisms for tumour cell sensitivity to TNF-alpha and potential therapeutic applications. Curr Pharm Biotechnol. 2001 Jun;2(2):119-30.
207. Liu R, Li B, Qiu M. Elevated superoxide production by active H-ras enhances human lung WI-38VA-13 cell proliferation, migration and resistance to TNF-alpha. Oncogene. 2001 Mar 22;20(12):1486-96.
208. Delhalle S, Deregowski V, Benoit V, Merville MP, Bours V. NF-kappaB-dependent MnSOD expression protects adenocarcinoma cells from TNF-alpha-induced apoptosis. Oncogene. 2002 May 30;21(24):3917-24.
209. Giardina C, Boulares H, Inan MS. NSAIDs and butyrate sensitize a human colorectal cancer cell line to TNF-alpha and Fas ligation: the role of reactive oxygen species. Biochim Biophys Acta. 1999 Jan 11;1448(3):425-38.
210. Berman KS, Verma UN, Harburg G, Minna JD, Cobb MH, Gaynor RB. Sulindac enhances tumor necrosis factoralpha- mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-kappaB. Clin Cancer Res. 2002 Feb;8(2):354-60.
211. Totzke G, Schulze-Osthoff K, Janicke RU. Cyclooxygenase-2 (COX-2) inhibitors sensitize tumor cells specifically to death receptor-induced apoptosis independently of COX-2 inhibition. Oncogene. 2003 Sep 11;22(39):8021-30.
212. Yasui H, Adachi M, Imai K. Combination of tumor necrosis factor-alpha with sulindac augments its apoptotic potential and suppresses tumor growth of human carcinoma cells in nude mice. Cancer. 2003 Mar 15;97(6):1412-20.
213. Fulda S, Debatin KM. IFNgamma sensitizes for apoptosis by upregulating caspase-8 expression through the Stat1 pathway. Oncogene. 2002 Apr 4;21(15):2295-308.
214. Lienard D, Eggermont AM, Koops HS, Kroon B, Towse G, Hiemstra S, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res. 1999 Oct;9(5):491-502.
215. Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Lienard D, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996 Dec;224(6):756-64; discussion 64-5.
216. Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res. 2004;91:137-68.
217. Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol. 2009 Nov 10;27(32):5459-68.
218. Chopin V, Slomianny C, Hondermarck H, Le Bourhis X. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Exp Cell Res. 2004 Aug 15;298(2):560-73.
219. Duverger V, Murphy AM, Sheehan D, England K, Cotter TG, Hayes I, et al. The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF). Br J Cancer. 2004 May 17;90(10):2025-31.
220. Beyaert R, Vanhaesebroeck B, Suffys P, Van Roy F, Fiers W. Lithium chloride potentiates tumor necrosis factormediated cytotoxicity in vitro and in vivo. Proc Natl Acad Sci U S A. 1989 Dec;86(23):9494-8.
221. Schotte P, Van Loo G, Carpentier I, Vandenabeele P, Beyaert R. Lithium sensitizes tumor cells in an NF-kappa Bindependent way to caspase activation and apoptosis induced by tumor necrosis factor (TNF). Evidence for a role of the TNF receptor-associated death domain protein. J Biol Chem. 2001 Jul 13;276(28):25939-45.
222. Song L, Zhou T, Jope RS. Lithium facilitates apoptotic signaling induced by activation of the Fas death domaincontaining receptor. BMC Neurosci. 2004 May 24;5:20.
223. Hanada M, Feng J, Hemmings BA. Structure, regulation and function of PKB/AKT--a major therapeutic target. Biochim Biophys Acta. 2004 Mar 11;1697(1-2):3-16.
224. Diarra-Mehrpour M, Arrabal S, Jalil A, Pinson X, Gaudin C, Pietu G, et al. Prion protein prevents human breast carcinoma cell line from tumor necrosis factor alpha-induced cell death. Cancer Res. 2004 Jan 15;64(2):719-27.
225. Zhang L, Himi T, Morita I, Murota S. Inhibition of phosphatidylinositol-3 kinase/Akt or mitogen-activated protein kinase signaling sensitizes endothelial cells to TNF-alpha cytotoxicity. Cell Death Differ. 2001 May;8(5):528-36.
226. Nishida S, Yoshioka S, Kinoshita-Kimoto S, Kotani M, Tsubaki M, Fujii Y, et al. Pretreatment with PKC inhibitor triggers TNF-alpha induced apoptosis in TNF-alpha-resistant B16 melanoma BL6 cells. Life Sci. 2003 Dec 26;74(6):781-92.
227. Delmas D, Rebe C, Lacour S, Filomenko R, Athias A, Gambert P, et al. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J Biol Chem. 2003 Oct 17;278(42):41482-90.
228. Delmas D, Rebe C, Micheau O, Athias A, Gambert P, Grazide S, et al. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Oncogene. 2004 Nov 25;23(55):8979-86.
229. Bible KC, Lensing JL, Nelson SA, Lee YK, Reid JM, Ames MM, et al. Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points. Clin Cancer Res. 2005 Aug 15;11(16):5935-41.
230. Demidenko ZN, Blagosklonny MV. Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res. 2004 May 15;64(10):3653-60.
231. Mocellin S, Costa R, Nitti D. RNA interference: ready to silence cancer? J Mol Med. 2006 Jan;84(1):4-15.
232. Wang X, Li N, Liu B, Sun H, Chen T, Li H, et al. A novel human phosphatidylethanolamine-binding protein resists tumor necrosis factor alpha-induced apoptosis by inhibiting mitogen-activated protein kinase pathway activation and phosphatidylethanolamine externalization. J Biol Chem. 2004 Oct 29;279(44):45855-64.
233. Leist M, Jaattela M. Burning up TNF toxicity for cancer therapy. Nat Med. 2002 Jul;8(7):667-8.
234. Greenberger S, Shaish A, Varda-Bloom N, Levanon K, Breitbart E, Goldberg I, et al. Transcription-controlled gene therapy against tumor angiogenesis. J Clin Invest. 2004 Apr;113(7):1017-24.
235. Li L, Thomas RM, Suzuki H, De Brabander JK, Wang X, Harran PG. A small molecule Smac mimic potentiates TRAIL- and TNFalpha-mediated cell death. Science. 2004 Sep 3;305(5689):1471-4.
236. Anderson GM, Nakada MT, DeWitte M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol. 2004 Aug;4(4):314-20.
237. Tada Y, J OW, Takenaga K, Takiguchi Y, Tatsumi K, Kuriyama T, et al. Expression of the TNF-alpha gene on mouse lung carcinoma cells suppresses spontaneous lung metastasis without affecting tumorigenicity. Oncol Rep. 2002 May-Jun;9(3):585-8.
238. Ortega AL, Carretero J, Obrador E, Gambini J, Asensi M, Rodilla V, et al. Tumor cytotoxicity by endothelial cells. Impairment of the mitochondrial system for glutathione uptake in mouse B16 melanoma cells that survive after in vitro interaction with the hepatic sinusoidal endothelium. J Biol Chem. 2003 Apr 18;278(16):13888-97.
239. Renard N, Lienard D, Lespagnard L, Eggermont A, Heimann R, Lejeune F. Early endothelium activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumour necrosis factor alpha (rTNF alpha). Int J Cancer. 1994;57(5):656-63.
240. Fraker DL, Alexander HR, Andrich M, Rosenberg SA. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. J Clin Oncol. 1996;14(2):479-89.
241. Lienard D, Eggermont AM, Koops HS, Kroon B, Towse G, Hiemstra S, et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study. Melanoma Res. 1999;9(5):491-502.
242. Rossi CR, Foletto M, Mocellin S, Pilati P, Lise M. Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases. Ann Surg Oncol. 2004 Feb;11(2):173-7.
243. van Etten B, van Geel AN, de Wilt JH, Eggermont AM. Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol. 2003 Jan-Feb;10(1):32-7.
244. Eggermont AM, Schraffordt Koops H, Klausner JM, Kroon BB, Schlag PM, Lienard D, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience. Ann Surg. 1996;224(6):756-64; discussion 64-5.
245. Gutman M, Inbar M, Lev-Shlush D, Abu-Abid S, Mozes M, Chaitchik S, et al. High dose tumor necrosis factor-alpha and melphalan administered via isolated limb perfusion for advanced limb soft tissue sarcoma results in a >90% response rate and limb preservation. Cancer. 1997;79(6):1129-37.
246. Plaat BE, Molenaar WM, Mastik MF, Koudstaal J, van den Berg E, Koops HS, et al. Hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan in patients with locally advanced soft tissue sarcomas: treatment response and clinical outcome related to changes in proliferation and apoptosis. Clin Cancer Res. 1999;5(7):1650-7.
247. Rossi CR, Foletto M, Di Filippo F, Vaglini M, Anza M, Azzarelli A, et al. Soft tissue limb sarcomas: Italian clinical trials with hyperthermic antiblastic perfusion. Cancer. 1999;86(9):1742-9.
248. Lejeune FJ, Pujol N, Lienard D, Mosimann F, Raffoul W, Genton A, et al. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol. 2000;26(7):669-78.
249. Komdeur R, Plaat BE, Hoekstra HJ, Molenaar WM, Hollema H, van den Berg E, et al. Expression of P-glycoprotein, multidrug resistance-associated protein 1, and lung resistance-related protein in human soft tissue sarcomas before and after hyperthermic isolated limb perfusion with tumor necrosis factor-alpha and melphalan. Cancer. 2001;91(10):1940-8.
250. Noorda EM, Vrouenraets BC, Nieweg OE, van Coevorden F, van Slooten GW, Kroon BB. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities. Cancer. 2003 Oct 1;98(7):1483-90.
251. Rossi C, Mocellin C, Pilati P, Foletto M, Quintieri L, Desalvo G, et al. Hyperthermic isolated perfusion with lowdose TNFa and doxorubicin for the treatment of limb threatening soft tissue sarcomas: a phase II study. Annals of Surgical Oncology. 2005;in press.
252. Alexander HR, Bartlett DL, Libutti SK, Fraker DL, Moser T, Rosenberg SA. Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol. 1998;16(4):1479-89.
253. Alexander HR, Libutti SK, Bartlett DL, Puhlmann M, Fraker DL, Bachenheimer LC. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res. 2000;6(8):3062-70.
254. Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR. Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery. 2001;129(2):176-87.
255. Feldman ED, Wu PC, Beresneva T, Helsabeck C, Rodriguez M, Bartlett DL, et al. Treatment of patients with unresectable primary hepatic malignancies using hyperthermic isolated hepatic perfusion. J Gastrointest Surg. 2004 Feb;8(2):200-7.